-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
us" style='margin:10px 0px;padding:0px;max-width:100%;color:#333333;letter-spacing:0.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。92%(3.
7%vs47.
6%)，9(5vs14)。92%92%
8%，43.
2%）296（57.
8%，42.
2%），14，141(47.
6%)，11(3.
7%)；156(52.
7%)，13(4.
4%)；14，5；97，262。，92%，92%，9。As of March 9, 2021, based on 294 prokruamide treatment group (males accounted for 56.
8%, female accounted for 43.
2%) and 296 placebo control group (male accounted for 57.
8%, female accounted for 42.
2%) The data analysis of the subjects showed that on the 14th day after treatment, the number of deaths in the control group was 141 (47.
6%), and the number of deaths in the procrulamide treatment group was 11 (3.
7%); the number of new ventilator users in the control group was 156 People (52.
7%), 13 people (4.
4%) in the procruamide treatment group; the median length of hospital stay was 14 days in the control group and 5 days in the procruamide treatment group; the number of discharged patients in the control group was 97 people, and There were 262 people in the Klulamide treatment group.
The results show that the S & P g Lu amine will crown a new death in patients with severe reduced risk by 92% , the new ventilator risk reduction of 92% use occurs, hospitalization time by 9 days .
Cape grams Lu amine will crown a new death in patients with severe risk of reducing by 92% the new ventilator risk reduction of 92% use occurs, hospitalization time by 9 days .
Hospital stay shortened by 9 days
7%
6 % [1]
7%
6 % [1]
7%
7% 3.
7%
6 % [1]
6 % [1] % [1] [1]
4%
7%
1%
8%
Tong Youzhi, founder, chairman and chief executive officer of Pioneer Pharmaceutical, said:
Dr.
Tong Youzhi, founder, chairman and chief executive officer of Pioneer Pharmaceutical, said:Dr.
us" style="margin:0px;padding:0px 12px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;font-size:14px;letter-spacing:1px;line-height:2;">
Of this present clinical trials for the treatment of patients crown is done in a very serious epidemic in Brazil twelve hospitals in the state of Amazonas, the subject of a viral infection and last year completed clinical trials in light of new crown disease treatment is quite different from the current state of Amazonas The vast majority of patients are infected with the P1 mutated new coronavirus, and its transmission and lethality have increased significantly.
We are very pleased to see that procrulamide in severely mutated severe treatment can also significantly reduce the mortality of patients with new coronary disease, save the lives of patients, and greatly reduce new mechanical ventilation and shorten the hospital stay of patients, alleviating local public health care The scarcity of resources.
Light outstanding efficacy disease, severe, critically ill patients based on new crown, and we look forward to an early Puke Lu amine drugs new crown full range of effective and safe for use on clinical.
The clinical trials for the treatment of coronavirus patients were completed in twelve hospitals in the Amazon state where the epidemic in Brazil is very serious.
The virus infection of the subjects is very different from the clinical trials for the treatment of mild and moderate new coronaviruses completed last year.
At present, most of the Amazon state All patients were infected with the P1 mutated new coronavirus, and its transmission and lethality increased significantly.
We are very pleased to see that procrulamide in severely mutated severe treatment can also significantly reduce the mortality of patients with new coronary disease, save the lives of patients, and greatly reduce new mechanical ventilation and shorten the hospital stay of patients, alleviating local public health care The scarcity of resources.
Light outstanding efficacy disease, severe, critically ill patients based on new crown, and we look forward to an early Puke Lu amine drugs new crown full range of effective and safe for use on clinical.
2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。
2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。
2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。
2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。
2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。
2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。2021311 （：9939.
HK，：“”），：WHO5.
6634.
011.
653，5.
6180.
255.
368（p0.
0001）。92%(3.
7%vs47.
6%)，9(5vs14)。92%(3.
7%vs47.
6%)，9(5vs14)。92%92%
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>（NCT04728802）、、、，。588，“+”“+”。，300mg，14。，300mg，14。14（WHO 8）。（NCT04728802）、、、，。588，“+”“+”。，300mg，14。，300mg，14。14（WHO 8）。（NCT04728802）、、、，。588，“+”“+”。，300mg，14。，300mg，14。14（WHO 8）。1px;padding:0px;max-width:100%;clear:both;min-height:1em;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;text-indent:32px;background:white;box-sizing:border-box ;'>
8%，43.
2%）296（57.
8%，42.
2%），14，141(47.
6%)，11(3.
7%)；156(52.
7%)，13(4.
4%)；14，5；97，262。，92%，92%，9。As of March 9, 2021, based on 294 prokruamide treatment group (males accounted for 56.
8%, female accounted for 43.
2%) and 296 placebo control group (male accounted for 57.
8%, female accounted for 42.
2%) The data analysis of the subjects showed that on the 14th day after treatment, the number of deaths in the control group was 141 (47.
6%), and the number of deaths in the procrulamide treatment group was 11 (3.
7%); the number of new ventilator users in the control group was 156 People (52.
7%), 13 people (4.
4%) in the procruamide treatment group; the median length of hospital stay was 14 days in the control group and 5 days in the procruamide treatment group; the number of discharged patients in the control group was 97 people, and There were 262 people in the Klulamide treatment group.
The results show that the S & P g Lu amine will crown a new death in patients with severe reduced risk by 92% , the new ventilator risk reduction of 92% use occurs, hospitalization time by 9 days .
Cape grams Lu amine will crown a new death in patients with severe risk of reducing by 92% the new ventilator risk reduction of 92% use occurs, hospitalization time by 9 days .
Hospital stay shortened by 9 days
544px;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
| | Prokalamide treatment group (N=294) | Placebo control group (N=296) | ||
| | Number of people | percentage | Number of people | percentage |
| mortality rate | 11 | 3. 7% | 141 | 47. 6 % [1] |
| The number of days in hospital (Median time) | 5 days | 14 days | ||
| New use of ventilator | 13 | 4. | 156 | 52. |
| Discharged | 262 | 89. | 97 | 32. |
Prokalamide treatment group
(N=294)
Placebo control group
(N=296)
Number of people
percentage
Number of people
percentage
mortality rate
11
3.
7%
141
47.
6 % [1]
The number of days in hospital
(Median time)
5 days
14 days
New use of ventilator
13
4.
4%
156
52.
7%
Discharged
262
89.
1%
97
32.
8%
Prokalamide treatment group
(N=294)
Placebo control group
(N=296)
Prokalamide treatment group
(N=294)
Prokalamide treatment group
Prokramide treatment group Prokramide treatment group Prokramide treatment group(N=294)
(N=294) (n=294) (n=294)Placebo control group
(N=296)
Placebo control group
Placebo control group placebo control group placebo control group(N=296)
(N=296) (n=296) (n=296)Number of people
percentage
Number of people
percentage
Number of people
Number of people
Number of peoplepercentage
percentage
percentageNumber of people
Number of people
Number of peoplepercentage
percentage
percentagemortality rate
11
3.
7%
141
47.
6 % [1]
mortality rate
mortality rate
mortality rate11
11
113.
7%
3.
7% 3.
7%
141
141
14147.
6 % [1]
47.
6 % [1]
6 % [1] % [1] [1]
The number of days in hospital
(Median time)
5 days
14 days
The number of days in hospital
(Median time)
The number of days in hospital
The number of days in hospital(Median time)
(Median time)5 days
5 days
5 days14 days
14 days
14 daysNew use of ventilator
13
4.
4%
156
52.
7%
New use of ventilator
New use of ventilator
New use of ventilator13
13
13 4.
4%
4.
4%
4%
156
156
156 52.
7%
52.
7%
7%
Discharged
262
89.
1%
97
32.
8%
Discharged
Discharged
Discharged262
262
262 89.
1%
89.
1%
1%
97
97
97 32.
8%
32.
8%
8%
544px;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
us" style='margin:0px;padding:0px 12px;max-width:100%;text-align:justify;white-space:normal;font-family:-apple-system-font, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;background-color:#FFFFFF;font-size:14px;line-height:2;letter-spacing:1px;color:#3E3E3E;box-sizing:border-box ;overflow-wrap:break-word ;'>Dr.Tong Youzhi, founder, chairman and chief executive officer of Pioneer Pharmaceutical, said:
Dr.
Tong Youzhi, founder, chairman and chief executive officer of Pioneer Pharmaceutical, said:Dr.
us" style="margin:0px;padding:0px 12px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;font-size:14px;letter-spacing:1px;line-height:2;">
Special thanks to all those involved in Dr.
Special thanks to all those involved in Dr.
Of this present clinical trials for the treatment of patients crown is done in a very serious epidemic in Brazil twelve hospitals in the state of Amazonas, the subject of a viral infection and last year completed clinical trials in light of new crown disease treatment is quite different from the current state of Amazonas The vast majority of patients are infected with the P1 mutated new coronavirus, and its transmission and lethality have increased significantly.
We are very pleased to see that procrulamide in severely mutated severe treatment can also significantly reduce the mortality of patients with new coronary disease, save the lives of patients, and greatly reduce new mechanical ventilation and shorten the hospital stay of patients, alleviating local public health care The scarcity of resources.
Light outstanding efficacy disease, severe, critically ill patients based on new crown, and we look forward to an early Puke Lu amine drugs new crown full range of effective and safe for use on clinical.
The clinical trials for the treatment of coronavirus patients were completed in twelve hospitals in the Amazon state where the epidemic in Brazil is very serious.
The virus infection of the subjects is very different from the clinical trials for the treatment of mild and moderate new coronaviruses completed last year.
At present, most of the Amazon state All patients were infected with the P1 mutated new coronavirus, and its transmission and lethality increased significantly.
We are very pleased to see that procrulamide in severely mutated severe treatment can also significantly reduce the mortality of patients with new coronary disease, save the lives of patients, and greatly reduce new mechanical ventilation and shorten the hospital stay of patients, alleviating local public health care The scarcity of resources.
Light outstanding efficacy disease, severe, critically ill patients based on new crown, and we look forward to an early Puke Lu amine drugs new crown full range of effective and safe for use on clinical.
